Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 6;27(7):2365.
doi: 10.3390/molecules27072365.

Flavonoids in Treatment of Chronic Kidney Disease

Yi-Ling Cao  1 , Ji-Hong Lin  2 , Hans-Peter Hammes  2 , Chun Zhang  1
Affiliations
Review

Flavonoids in Treatment of Chronic Kidney Disease

Yi-Ling Cao et al. Molecules. .

Abstract

Chronic kidney disease (CKD) is a progressive systemic disease, which changes the function and structure of the kidneys irreversibly over months or years. The final common pathological manifestation of chronic kidney disease is renal fibrosis and is characterized by glomerulosclerosis, tubular atrophy, and interstitial fibrosis. In recent years, numerous studies have reported the therapeutic benefits of natural products against modern diseases. Substantial attention has been focused on the biological role of polyphenols, in particular flavonoids, presenting broadly in plants and diets, referring to thousands of plant compounds with a common basic structure. Evidence-based pharmacological data have shown that flavonoids play an important role in preventing and managing CKD and renal fibrosis. These compounds can prevent renal dysfunction and improve renal function by blocking or suppressing deleterious pathways such as oxidative stress and inflammation. In this review, we summarize the function and beneficial properties of common flavonoids for the treatment of CKD and the relative risk factors of CKD.

Keywords: chronic kidney disease; flavonoids; inflammation; nephroprotection; oxidative stress.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Chemical structures and classification of flavonoids.
Figure 2
Figure 2
The chemical structures of the flavonoids discussed in CKD. (a–t): the flavonoid substances and their structural formulas mentioned in CKD.
Figure 3
Figure 3
The nephroprotective mechanisms of flavonoids in CKD.
See this image and copyright information in PMC

References

    1. Kumari A., Karnatak M., Singh D., Shankar R., Jat J.L., Sharma S., Yadav D., Shrivastava R., Verma V.P. Current scenario of artemisinin and its analogues for antimalarial activity. Eur. J. Med. Chem. 2019;163:804–829. doi: 10.1016/j.ejmech.2018.12.007. - DOI - PubMed
    1. Kingston D.G.I., Cassera M.B. Antimalarial Natural Products. Prog. Chem. Org. Nat. Prod. 2022;117:1–106. - PubMed
    1. Habtemariam S. Berberine pharmacology and the gut microbiota: A hidden therapeutic link. Pharmacol. Res. 2020;155:104722. doi: 10.1016/j.phrs.2020.104722. - DOI - PubMed
    1. Jha V., Garcia-Garcia G., Iseki K., Li Z., Naicker S., Plattner B., Saran R., Wang A.Y.-M., Yang C.-W. Chronic kidney disease: Global dimension and perspectives. Lancet. 2013;382:260–272. doi: 10.1016/S0140-6736(13)60687-X. - DOI - PubMed
    1. Coresh J., Selvin E., Stevens L.A., Manzi J., Kusek J.W., Eggers P., Van Lente F., Levey A.S. Prevalence of Chronic Kidney Disease in the United States. JAMA: J. Am. Med Assoc. 2007;298:2038–2047. doi: 10.1001/jama.298.17.2038. - DOI - PubMed